Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (3): 302-307.doi: 10.3969/j.issn.1000-6621.2019.03.011
• Original Articles • Previous Articles Next Articles
Xia YU1,Jing-jing LUO1,Li-ping ZHAO1,Yang XU2,Qian LIANG1,Yi-feng MA1,Ling-ling DONG1,Hai-rong HUANG1()
Received:
2018-09-20
Online:
2019-03-10
Published:
2019-03-15
Contact:
Hai-rong HUANG
E-mail:huanghairong@tb123.org
Xia YU,Jing-jing LUO,Li-ping ZHAO,Yang XU,Qian LIANG,Yi-feng MA,Ling-ling DONG,Hai-rong HUANG. In vitro activity of meropenem against non-tuberculous Mycobacteria[J]. Chinese Journal of Antituberculosis, 2019, 41(3): 302-307. doi: 10.3969/j.issn.1000-6621.2019.03.011
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.03.011
标准菌株号 | 拉丁文名称 | 中文名称 | MIC(μg/ml) | |
---|---|---|---|---|
RGM 菌种 | ||||
ATCC 19977 | Mycobacterium abscessus | 脓肿分枝杆菌 | 64 | |
ATCC 27406 | Mycobacterium agri | 田野分枝杆菌 | 16 | |
ATCC 27280 | Mycobacterium aichiense | 爱知分枝杆菌 | 0.25 | |
ATCC 23366 | Mycobacterium aurum | 金色分枝杆菌 | 2 | |
ATCC 33464 | Mycobacterium austroafricanum | 南非分枝杆菌 | >64 | |
ATCC 14472 | Mycobacterium chelonae | 龟分枝杆菌 | >64 | |
ATCC 19627 | Mycobacterium chitae | 千田分枝杆菌 | 0.5 | |
ATCC 27278 | Mycobacterium chubuense | 楚布分枝杆菌 | 8 | |
DSM 44829 | Mycobacterium cosmeticum | 美容品分枝杆菌 | 2 | |
ATCC 19340 | Mycobacterium diernhoferi | 迪氏分枝杆菌 | 0.5 | |
ATCC 35219 | Mycobacterium fallax | 诡诈分枝杆菌 | >64 | |
ATCC 6841 | Mycobacterium fortuitum | 偶发分枝杆菌 | 4 | |
ATCC 27726 | Mycobacterium gadium | 加地斯分枝杆菌 | 0.25 | |
ATCC 43909 | Mycobacterium gilvum | 浅黄分枝杆菌 | 4 | |
ATCC BAA-955 | Mycobacterium goodii | 古德分枝杆菌 | 4 | |
DSM 44124 | Mycobacterium mucogenicum | 产黏液分枝杆菌 | 1 | |
ATCC 25795 | Mycobacterium neoaurum | 新金色分枝杆菌 | 1 | |
ATCC 27023 | Mycobacterium obuense | 奥布分枝杆菌 | 32 | |
ATCC 19686 | Mycobacterium parafortuitum | 副偶发分枝杆菌 | 8 | |
DSM 43271 | Mycobacterium peregrinum | 外来分枝杆菌 | 0.25 | |
ATCC 11758 | Mycobacterium phlei | 草分枝杆菌 | 32 | |
ATCC 33776 | Mycobacterium porcinum | 猪分枝杆菌 | 2 | |
ATCC 35154 | Mycobacterium pulveris | 灰尘分枝杆菌 | 0.25 | |
ATCC 35796 | Mycobacterium senegalense | 塞内加尔分枝杆菌 | 8 | |
ATCC 700731 | Mycobacterium septicum | 败血症分枝杆菌 | 0.25 | |
ATCC 25275 | Mycobacterium simiae | 猿分枝杆菌 | 0.25 | |
ATCC 19420 | Mycobacterium smegmatis | 耻垢分枝杆菌 | 2 | |
ATCC 19527 | Mycobacterium thermoresistibile | 抗热分枝杆菌 | 4 | |
ATCC 27282 | Mycobacterium tokaiense | 东海分枝杆菌 | 1 | |
ATCC 15483 | Mycobacterium vaccae | 母牛分枝杆菌 | 16 | |
标准菌株号 | 拉丁文名称 | 中文名称 | MIC(μg/ml) | |
SGM 菌种 | ||||
ATCC 25276 | Mycobacterium asiaticum | 亚洲分枝杆菌 | 8 | |
ATCC 25291 | Mycobacterium avium | 鸟分枝杆菌 | 64 | |
DSM 44243 | Mycobacterium celatum | 隐蔽分枝杆菌 | 16 | |
ATCC 15754 | Mycobacterium gastri | 胃分枝杆菌 | 0.5 | |
ATCC 14470 | Mycobacterium gordonae | 戈登分枝杆菌 | 0.25 | |
ATCC 13950 | Mycobacterium intracellulare | 胞内分枝杆菌 | 64 | |
ATCC 12478 | Mycobacterium kansasii | 堪萨斯分枝杆菌 | 64 | |
ATCC 19422 | Mycobacterium microti | 田鼠分枝杆菌 | 2 | |
ATCC 19530 | Mycobacterium nonchromogenicum | 不产色分枝杆菌 | 1 | |
DSM 44648 | Mycobacterium parascrofulaceum | 副偶发分枝杆菌 | 32 | |
ATCC 19981 | Mycobacterium scrofulaceum | 瘰疬分枝杆菌 | 64 | |
ATCC 35799 | Mycobacterium szulgai | 苏尔加分枝杆菌 | 0.5 | |
ATCC 15755 | Mycobacterium terrae | 土分枝杆菌 | 64 | |
ATCC 23292 | Mycobacterium triviale | 次要分枝杆菌 | >64 | |
ATCC 27294 | Mycobacterium tuberculosis (H37Rv) | 结核分枝杆菌 | 2 | |
ATCC 19250 | Mycobacterium xenopi | 蟾分枝杆菌 | 64 |
分类 | 拉丁名称 | 中文名称 | 菌株数量 | MIC (μg/ml) |
---|---|---|---|---|
SGM | Mycobacterium arupense | 阿普罗分枝杆菌 | 4 | 0.5(1),16(1),>64(2) |
Mycobacterium xenopi | 蟾分枝杆菌 | 4 | 32(4) | |
Mycobacterium szulgai | 苏尔加分枝杆菌 | 3 | 16(2),32(1) | |
Mycobacterium parascrofulaceum | 副瘰疬分枝杆菌 | 1 | 16(1) | |
Mycobacterium terrae | 土分枝杆菌 | 1 | >64(1) | |
Mycobacterium malmoense | 玛尔摩分枝杆菌 | 1 | 8(1) | |
RGM | Mycobacterium chelonae | 龟分枝杆菌 | 3 | 0.25(1),4(1),>64(1) |
Mycobacterium holsaticum | 荷尔斯泰因分枝杆菌 | 1 | >64 | |
Mycobacterium massiliense | 马赛分枝杆菌 | 3 | >64(3) |
[1] |
Falkinham JO, 3rd . Ecology of nontuberculous mycobacteria-where do human infections come from? Semin Respir Crit Care Med, 2013,34(1):95-102.
doi: 10.1055/s-00000075 URL |
[2] |
Yu X, Liu P, Liu G , et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect, 2016,73(6):558-567.
doi: 10.1016/j.jinf.2016.08.020 URL pmid: 27717784 |
[3] |
Lin C, Russell C, Soll B , et al. Increasing prevalence of nontuberculous mycobacteria in respiratory specimens from US-Affiliated Pacific Island Jurisdictions. Emerg Infect Dis, 2018,24(3):485-491.
doi: 10.3201/eid2403.171301 URL |
[4] | de Mello KG, Mello FC, Borga L , et al. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993—2011. Emerg Infect Dis, 2013,19(3):393-399. |
[5] |
Li G, Pang H, Guo Q , et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents, 2017,49(3):364-374.
doi: 10.1016/j.ijantimicag.2016.10.024 URL pmid: 28131606 |
[6] | Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards Institute Document M24-A2Susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. second ed. Wayne, PA: CLSI, 2011. |
[7] |
Luo J, Yu X, Jiang G , et al. In vitro activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob agents chemother, 2018,62(7):e00072-18.
doi: 10.1128/AAC.00072-18 URL pmid: 29760127 |
[8] |
Coban AY, Bilgin K, Tasdelen Fisgin N , et al. Effect of mero-penem against multidrug-resistant Mycobacterium tuberculosis. J chemother, 2008,20(3):395-396.
doi: 10.1179/joc.2008.20.3.395 URL pmid: 1860660232 |
[9] |
England K, Boshoff HI, Arora K , et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrobial Agents Chemother, 2012,56(6):3384-3387.
doi: 10.1128/AAC.05690-11 URL |
[10] |
Horita Y, Maeda S, Kazumi Y , et al. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors. Antimicrob Agents Chemother, 2014,58(11):7010-7014.
doi: 10.1128/AAC.03539-14 URL pmid: 25224000 |
[11] |
中华医学会结核病学分会, 分枝杆菌菌种中文译名原则专家共识编写组. 分枝杆菌菌种中文译名原则专家共识. 中华结核和呼吸杂志, 2018,41(7):522-528.
doi: 10.3760/cma.j.issn.1001-0939.2018.07.003 URL |
[12] |
Pang Y, Zheng H, Tan Y , et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother, 2017,61(5):e02627-16.
doi: 10.1128/AAC.02627-16 URL pmid: 28242674 |
[13] |
Santin M, Barrabeig I, Malchair P , et al. Pulmonary infections with nontuberculous mycobacteria, Catalonia, Spain, 1994-2014. Emerg Infect Dis, 2018,24(6):1091-1094.
doi: 10.3201/eid2406.172095 URL pmid: 29774836 |
[14] |
Brode SK, Marchand-Austin A, Jamieson FB , et al. Pulmonary versus nonpulmonary nontuberculous mycobacteria, Ontario, Canada. Emerg Infect Dis, 2017,23(11):1898-1901.
doi: 10.3201/eid2311.170959 URL pmid: 29048292 |
[15] |
Zhang D, Wang Y, Lu J , et al. In vitro activity of β-lactams in combination with β-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother, 2016,60(1):393-399.
doi: 10.1128/AAC.01035-15 URL |
[16] |
Brown-Elliott BA, Killingley J, Vasireddy S , et al. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and nocardia by use of broth microdilution and etest. J Clin Microbiol, 2016,54(6):1586-1592.
doi: 10.1128/JCM.00298-16 URL |
[17] |
Bulik CC, Christensen H, Li P , et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother, 2010,54(2):804-810.
doi: 10.1128/AAC.01190-09 URL pmid: 19995927 |
[1] | Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65. |
[2] | Fan Jun, Wang Heng, Lan Tinglong, Dong Weijie, Tang Kai, Li Yuan, Yan Guangxuan, Xu Shangsheng, Kang Zhigang, Qin Shibing. Clinical characteristics and surgical outcomes of 12 cases of non-tuberculous mycobacterial spondylitis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 87-95. |
[3] | Chen Shuangshuang, Tian Lili, Wang Nenhan, Yang Xinyu, Zhao Yanfeng, Li Chuanyou, Dai Xiaowei. Analysis of in vitro antibacterial effects of 17 antibiotics against rapidly growing mycobacteria in the Beijing area [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1056-1062. |
[4] | Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076. |
[5] | Duan Hongfei. Diagnosis and treatment of nontuberculous mycobacteria diseases in the past 60 years [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 863-868. |
[6] | Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950. |
[7] | Zhang Hui, Ge Li, Zhang Yuhan, Feng Ruie. Clinicopathologic characteristics of 34 cases non-tuberculous mycobacterial disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 756-762. |
[8] | He Xiangrong, Chen Hua, Chen Pinru, Liang Feng, Ren Huili, Zhu Jialou, Hu Jinxing, Tan Yaoju. A case report and literature review of Mycobacterium asiaticum pulmonary disease [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 763-769. |
[9] | Cheng Mengli, Jiang Guanglu, Huo Fengmin, Xue Yi, Yu Xia. Evaluation of in vitro activity of fusidic acid against mycobacteria [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 461-466. |
[10] | Pei Shaojun, Ou Xichao. Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition) [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266. |
[11] | Gao Shan, Nie Wenjuan, Hou Dailun, Chu Naihui. Research progress on imaging manifestations of nontuberculosis mycobacterial pulmonary and application of new artificial intelligence technology [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 362-366. |
[12] | Zhang Yan, Wang Senlu, Rizwanguli Rehman, Liu Nianqiang, Wang Xinqi, Mao Hongkai, Wang Xiaomin, Cao Mingqin. Evaluation of the implementation effect of “Active Tuberculosis Screening+Full-Course Hospitalization” model for patient detection in Hotan Prefecture, Xinjiang Uygur Autonomous Region [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 145-150. |
[13] | Bao Liangliang, Wang Xinqi, Zhang Yan, Cao Mingqin. Qualitative evaluation of the implementation status of tuberculosis prevention and control in Southern Xinjiang Uygur Autonomous Region: qualitative interviews based on grounded theories [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 151-157. |
[14] | Zheng Guangmin, Wang Ting, Zhang Danni, Lei Yu, Yang Jieying, Wu Guifeng, Du Yuhua, Xiao Xincai. Evaluation on the implementation effect of different tuberculosis prevention and control management models during the 13th Five-Year Plan period in Guangzhou [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 199-205. |
[15] | Ma Shiran, Chen Suting, Huang Hairong, Duan Hongfei. In vitro inhibitory and intracellular bactericidal activity of omadacycline against Mycobacterium abscessus [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1442-1447. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||